Remegen Co., Ltd.
Clinical trials sponsored by Remegen Co., Ltd., explained in plain language.
-
New drug RC288 targets Hard-to-Treat tumors in early trial
Disease control Not yet recruitingThis study tests a new drug called RC288 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 326 adults aged 18 to 75 with good overall health will take …
Phase: PHASE1, PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug aims to protect lungs in autoimmune patients
Disease control Not yet recruitingThis Phase 3 trial tests whether the drug telitacicept can slow the decline in lung function in people with connective tissue disease-related interstitial lung disease (CTD-ILD). About 260 adults with conditions like rheumatoid arthritis or lupus and confirmed lung scarring will …
Phase: PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC